Free for patients! Initially available in Austria and Germany, and soon in the US.

How I’m trying to beat my long list of “I should really...”

“We have to create solutions in diabetes that are as addictive as the iPhone.”

“We need to support people at risk and prevent diabetes before it even happens.”

People with type 2 diabetes are far more willing than their doctors perceive to take action to achieve A1c goals

New study shows that beta cell fragility may contribute to the risk of both type 1 and type 2 diabetes.

Team Novo Nordisk athletes with diabetes dispel myths and stigma.

No fingersticks needed? Plus, a look at the “thinnest CGM ever” from Dexcom and Verily

Details for Dexcom July 21 Advisory Panel meeting posted. How to submit a written statement to the FDA or attend in person.

Saturday, August 27; $10 early bird registration fee

Tax revenue will be invested in primary school sports in England.

Matchstick-sized device implanted under the skin every 6-12 months. New data in over 4,000 people demonstrates it is safe for heart health. Could it launch by late 2017?

The diaTribe Foundation’s 2016 gathering shares need for earlier treatment, data integration, prevention, amplifying patient voices, and reducing stigma.

How close is the UN to achieving its goal of “halting the rise in diabetes and obesity” by 2025?

A call to action to make this invisible disease visible.

New ADA guidelines encourage interrupting long periods of sitting: improved blood glucose management and insulin sensitivity

Providers and patients will now see the same data - stay tuned for IBM Watson!

An 8-2 panel vote finds that benefits of using Dexcom’s G5 CGM for dosing insulin outweigh the risks; patient advocates provide compelling testimonies

80 days, 5 lbs of weight loss, and my strongest blood glucose numbers ever?

MannKind has re-launched the inhaled mealtime insulin, Afrezza, alongside new initiatives to promote the product